How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

49,670 results for

Hypertension Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

34821. Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: High-risk proliferative diabetic retinopathy (HR-PDR) eyes (as defined in section 2). BCVA at baseline > 20/320 (25 letters in the ETDRS Chart) in the study eye. Clear ocular media and adequate pupillary dilatation to permit good quality fundus photography. Intraocular pressure < 21 mmHg. Type I, or Type II diabetic subjects as defined by the WHO criteria of either gender, and aged ≥ 18 years. Women must (...) Verified: April 2013 Keywords provided by Association for Innovation and Biomedical Research on Light and Image: High Risk Proliferative Diabetic Retinopathy Diabetes Mellitus Type I, Type II Pegaptanib Panretinal Photocoagulation Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Retinal Diseases Diabetic Retinopathy Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Eye Diseases Diabetic Angiopathies

2011 Clinical Trials

34822. A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

) of Laboratory Values Related to Treatment [ Time Frame: Day 1 to up to Month 9 ] Participants whose laboratory examinations (hematology, blood chemistry and urinalysis) were considered by the investigator to be treatment emergent adverse experiences (TEAE) and related to treatment. Also indicated is whether the TEAE lab parameter caused the participant to discontinue from the study. Mean Intraocular Pressure at Month 9 [ Time Frame: Day 1 up to Month 9 ] Mean intraocular pressure at month 9 or the early (...) on endometrial biopsies and transvaginal ultraonogrphy (TVU) are summarized. Clinically significant results from the endometrial biopsies are results that are not benign. Abnormalities found during transvaginal ultrasonography (TVU) are detailed in the AE listings. Please refer to AE listings. Mean Blood Pressure Measurements at Week 36 [ Time Frame: approximately week 36 ] Mean systolic and diastolic blood pressure measurements taken at week 36 Participants With Treatment Emergent Adverse Experiences (TEAE

2011 Clinical Trials

34823. Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)

. schizophrenia etc. unstable diabetes, diabetes causing diabetic retinopathy addiction high blood pressure (max. 160/100 mmHg) instable or high level of intraocular pressure (i.e. > 27 mmHg) retinitis pigmentosa pathological nystagmus presence of an un-operated tumor anywhere in the body pregnant or breast-feeding women photo sensibility Fundus hypertonicus acute conjunctivitis Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor (...) -based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion. Secondary Outcome Measures : DA change in percent over baseline regarding the damage region of the tested visual field (computer-based high-resolution perimetry) [ Time Frame: Baseline - 8 weeks

2011 Clinical Trials

34824. MAPP Investigation of Pelvic Floor-Brain Neurobiologic Axis in IC/IBS and IBS

, multiple sclerosis, strokes, spinal cord injuries) or brain disorders prone to causing seizures; Patients experiencing impaired cognizance (mini mental score of < 15) and/or legally blind; Women who are pregnant or likely to conceive (women with potential for pregnancy must use contraceptive measures to be included); Patients with ulcerative and Crohns colitis; Patients with rectal prolapse, anal fissure, anal surgery or inflamed hemorrhoids. Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS (...) by the patient). Neurogenic bladder dysfunction (e.g.,) due to spinal cord injury, stroke, Parkinson's, MS, spina bifida, or diabetic cystopathy (reported by the patient or determined during a neurologic exam. Having had an augmentation cystoplasty (as reported by the patient). Having undergone a cystectomy, cystolysis, or neuroectomy as reported by the patient. Having a urethral stricture of less than 12 French (as reported by the patient). Urinalysis with >10 white blood cells per high-powered field

2011 Clinical Trials

34825. Intravitreal Sirolimus as Therapeutic Approach to Uveitis

and the usefulness of treatment of non-infectious uveitis using different doses of intravitreal injections of a drug called sirolimus. Current treatment options for uveitis include oral corticosteroids and drugs that weaken the immune system of the body (i.e., immunosuppressant drugs). Treatment using oral corticosteroids, especially for long periods, may cause many undesirable side effects and complications such as high blood sugar, high blood pressure, bone weakness, obesity, stomach ulcers, abnormal hair (...) -term use of immunosuppressant drugs may carry an increased risk of developing skin cancer as a result of the combination of the drugs and exposure to sunlight. The immunosuppressive drugs are very powerful and can cause serious side effects such as high blood pressure, kidney problems, and liver problems. Some side effects may not show up until years after the medicine is used. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment

2011 Clinical Trials

34826. A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

a novel reduced toxicity regimen for stem cell transplant with unrelated donors. Analysis will be geared to confirm if the study regimen, followed by an appropriately HLA-matched unrelated donor (MUD)or unrelated cord blood HSCT, can lead to durable donor engraftment with reasonable toxicity, inhibiting sickle erythropoiesis and limiting disease related organ toxicity in patients who are at high risk for morbidity and mortality associated with sickle cell disease (SCD). Study Design Go to Layout table (...) as 3 or more severe pain events per year in the 2 years prior to enrollment despite adequate supportive care measures and hydroxyurea trial (i.e. Hydroxyurea non-responders). Pain may occur in typical sites associated with vaso-occlusive painful events and cannot be explained by causes other than vaso-occlusion mediated by sickle cell disease. Recurrent priapism. Osteo-necrosis of multiple joints Evidence of Pulmonary Hypertension as evidenced by Tricuspid Regurgitation jet velocity (TRV) > 2.5 m/s

2011 Clinical Trials

34827. Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

effects (good and bad) it has on you and your cancer Find the highest dose of GO-203-2c that can be given without causing bad side effects Examine how much GO-203-2c is in the blood at certain times after it is given and how quickly the body gets rid of it Observe whether there is any effect of GO-203-2c on the size and activity of cancer in your body Condition or disease Intervention/treatment Phase Solid Tumors Drug: GO-203-2c Phase 1 Study Design Go to Layout table for study information Study Type (...) Sponsor: Genus Oncology, LLC Information provided by (Responsible Party): Genus Oncology, LLC Study Details Study Description Go to Brief Summary: This clinical trial is about testing GO-203-2c, which is a newly discovered compound that binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in many cancers). By binding to MUC1, GO-203-2c eventually causes tumor cell death in laboratory studies. This study is being done to: Test the safety of GO-203-2c and see what

2011 Clinical Trials

34828. Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

Cooperative Oncology Group (ECOG) performance status of 0 to 2 Willingness to participate after informed consent. Exclusion Criteria: Anaemia caused primarily by other factors than CIA. IV or oral iron treatment within 4 weeks prior to screening visit. Erythropoietin treatment within 4 weeks prior to screening visit. Blood transfusion within 4 weeks prior to screening visit. Imminent expectation of blood transfusion on part of treating physician. Iron overload or disturbances in utilization of iron (e.g (...) other clinical study (except chemotherapy protocol) within 3 months prior to screening. Untreated B12 or folate deficiency. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus. Contacts and Locations Go to Information from the National Library

2011 Clinical Trials

34829. Pazopanib as Single Agent in Advanced NETs

.Coronary artery bypass graft surgery 7.5.Symptomatic peripheral vascular disease 7.6.Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg]. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent (...) Study Details Study Description Go to Brief Summary: The incidence of new diagnosed patients with NET of the digestive tract including carcinoid and pancreatic islet cells tumors ranges from 2 to 10 per 100,000 in the western Countries (Kulke M, Mayer R. N Engl J Med 340:858-868, 1999). Despite of the low incidence, the prevalence of these tumors is high because of their relatively long survival estimated in 35% at 5 years for those patients with well or moderate differentiated tumors (Yao JC, et al

2011 Clinical Trials

34830. Adenosine Activity in Producing Venoarteriolar Reflexes

(as in lower limbs veins during prolonged standing) causes adenosine "wash out", which leads to local arterial vasoconstriction to reduce blood flow to the limb, which is, in fact, the purpose of VAR. if our hypothesis turns to be true, then when we will see exaggeration of the reflexes with adenosine blockade and vice versa, a decrease its abolishment with adenosine reuptake inhibition. Condition or disease Intervention/treatment Phase Venoarteriolar Reflex Drug: aminophylline Not Applicable Study Design (...) is the arteriolar vascocostriction response to venous congestion in the limb. The congestion is produced by lowering the limb below the heart level or increasing the soft tissue pressure (using a cuff)to above venous and below arteriolar pressure (to 40 mmHg). The vasoconstriction is assessed by comparing blood flow to the limb before and after the congestion. the units used for blood flow measurements are of flow: ml blood/100 ml tissue*sec^-1. Eligibility Criteria Go to Information from the National Library

2011 Clinical Trials

34831. Predicting Hypotension Related to Spinal Anesthesia

Go to Brief Summary: This study aims to identify women at risk of low blood pressure (hypotension) after the usual cesarean anesthetic - a spinal anesthetic. Hypotension may be caused by dehydration. We believe we can predict who will get hypotension by using two anesthesia monitors together with a passive leg raise (PLR) (legs elevated after a period spent reclining). The PLR will cause a shift of blood from the legs to the heart, and the monitors will detect the heart's response to tell (...) non-invasive blood pressure (BP) measurement difficult. It may also affect speed of onset and height of subarachnoid block due to increased epidural venous plexus engorgement and thecal sac compression resulting in more marked hypotension. Pregnancy induced hypertension (BP after 20wk greater than 140/90 with proteinuria) High risk of hemorrhage - where fluid volume expansion is planned prior to delivery (e.g. placenta previa, placenta accreta) Exclusion Criteria: Starting BP is less than 100

2011 Clinical Trials

34832. Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.

Left bundle branch block or pacemaker. Systolic blood pressure <120 mmHg, Heart rate <60 bpm, or AV block (PR˃240 mS or superior) on diagnosis. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01311700 Locations Layout table for location information (...) myocardial infarction might reduce the size of myocardial necrosis. Condition or disease Intervention/treatment Phase Myocardial Infarction Drug: Injectable (i.v.) metoprolol tartrate (up to 15 mg). Phase 4 Detailed Description: Acute myocardial infarction (AMI) is a chief cause of death worldwide. The best strategy to limit myocardial damage is to perform an early coronary reperfusion. However, despite reperfusion, the size of infarctions is many times large. Infarct size has been recently shown

2011 Clinical Trials

34833. The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy

: between the ages of 18 and 65 years old diagnosed with depression and being referred for ECT American Society of Anesthesiologists (ASA) score of 1 or 2 patient receiving ECT on an informal basis (i.e. consenting to treatment and able to give informed consent) Exclusion Criteria: pre-existing neurological disease or cognitive impairment co-morbid psychiatric diagnoses pre-existing hypertension severe respiratory tract disease major cardiovascular disease pacemakers cerebrovascular disorder (...) on memory. Condition or disease Intervention/treatment Phase Depression Drug: Ketamine Drug: Propofol Phase 4 Detailed Description: According to WHO statistics, depression is amongst the leading causes of disability worldwide. In its more severe forms, it can be life threatening. The most severe forms of depression, or those that fail to respond to chemical treatment are treated with electroconvulsive therapy (ECT). The treatment is highly effective, and undoubtedly saves lives, but a range of factors

2011 Clinical Trials

34834. Influenza Vaccine Trial in HIV Uninfected Pregnant Women

entry, or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) ≤ 12 weeks before study entry (nasal and topical steroids are allowed). Receipt of corticosteroids for preterm labor ≤ 14 days before study entry. Receipt of immunoglobulin or other blood products (with exception of Rho D immune globulin) ≤ 12 weeks prior to enrollment in this study or is scheduled to receive immunoglobulin or other blood products (with the exception of Rho D immune globulin) during (...) pregnancy or for the first 24 weeks after delivery. Receipt of IL2, IFN, GMCSF or other immune mediators ≤ 12 weeks before enrollment. Uncontrolled major psychiatric disorder. History of a severe adverse reaction to previous TIV. Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. Pregnancy complications (in the current pregnancy) such as pre-term labor, hypertension

2011 Clinical Trials

34835. Effect of Gastric Lavage in Preventing Feeding Problems in Babies Born With Meconium Stained Amniotic Fluid

suction done at birth is associated with long term risk for functional intestinal disorder. The sequence of prefeeding behaviour is disrupted in children who undergo gastric suction and it can delay initiation of breast feeding. Small elevation in mean arterial blood pressure, increased retching have also been reported The role of gastric lavage in preventing feeding problems and secondary meconium aspiration syndrome has not been systematically evaluated. If this procedure is not proven (...) stabilisation without any supporting evidence. It is believed that meconium is an irritant and its presence in stomach causes gastritis and vomiting and hence the basis for this practice. Orogastric tube insertion and subsequent gastric lavage is not without complications. Potential complications will be prevented and health resources will be saved if this procedure is not proven to be beneficial. Therefore the investigators decided to study if gastric lavage reduces incidence of vomiting and other feeding

2011 Clinical Trials

34836. Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer

not interrupt the using of the drugs that may cause QT prolongation during study. Subjects with meningioma, or with active central nervous system metastases as indicated by clinical symptoms. Subjects with liver metastases which ALT or AST > 1.5 x ULN. Treated or treating with EGFR or HER2 TKIs before study entry. Receiving any other antitumor therapy. Less than 4 weeks from the last clinical trial. Pregnant or breastfeeding women. Known history of hypersensitivity to cipatinib or any of it components (...) . Ongoing infection (determined by investigator). Subjects had any heart disease: coronary artery disease, arrhythmia need to treat, heart failure, LVEF < 50%, and any other heart disease that is determined as unfit for this study by investigator, etc. Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. Examples include, but are not limited to, hypertension, severe

2011 Clinical Trials

34837. Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE

emphasizes the use of lower tidal volumes with lower plateau pressures to avoid causing lung overdistension and ventilator associated lung injury (VILI)7; however, in the real world, some studies showed that strictly reduction of tidal volume to 6ml/kg PBW was modest in modern time, and was noticed only in patients with greater lung injury scores8. The benefit of VT strictly reduction to 6ml/kgPBW and its effect on VILI in patients with less severe ARDS whose Pplat are already below 30 cmH2O (...) tidal volume strategy ventilation accelerated the decline in plasma RAGE levels. These results suggest plasma RAGE level might be a reliable biomarker of alveolar epithelial injury in acute lung injury and may associated with ventilator induced lung injury6. Although, current approach to mechanical ventilation of a patient with ARDS emphasizes the use of lower tidal volumes with lower plateau pressures to avoid causing lung overdistension and ventilator associated lung injury (VILI)7; however

2011 Clinical Trials

34838. Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)

of labile hypertension, or history of poor compliance with an antihypertensive regimen). Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat. Patients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks (...) for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Panobinostat

2011 Clinical Trials

34839. Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

with coumarin-derivative anticoagulants Presence of acute or chronic liver, renal disease, or pancreatitis For all Arms, patients with poorly controlled diabetes mellitus, and/or with clinical signs, and/or steroid-induced diabetes mellitus; for Arm B, patients requiring insulin treatment History of gestational diabetes mellitus Known diagnosis of human immunodeficiency virus (HIV) infection For Arms A, C or D, patients with the following mood disorders as judged by the investigator or a psychiatrist (...) , or as result of patient's mood assessment questionnaire: Medically documented history of major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or patients with active severe personality disorders (defined according to DSM-IV). NOTE: for patients with psychotropic treatments ongoing at baseline, the dose and schedule should not be modified within

2011 Clinical Trials

34840. Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

. unstable angina, congestive heart failure or uncontrolled hypertension defined as greater than 160/100 mmHg despite use of antihypertensive medication), History of or presence of clinically significant ventricular or atrial tachyarrhythmias, Complete left bundle branch block or bifascicular block (right bundle branch block plus left anterior hemiblock) or use of ventricular-paced pacemaker Patients who are currently receiving treatment with any of the medications that have the potential to prolong (...) Party): M.D. Anderson Cancer Center Study Details Study Description Go to Brief Summary: The goal of this clinical research study is to learn if Tasigna® (nilotinib) can cause tumor cells to shrink and/or die in patients with GIST who are scheduled for surgery or may be eligible for surgery. The safety of this drug will be studied. Researchers also want to use imaging scans to study the changes in tumor size that may be caused by using nilotinib. Condition or disease Intervention/treatment Phase

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>